Altus Pharmaceuticals Homepage

Altus Pharmaceuticals® is focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases. Altus' in-depth knowledge of protein crystallization has resulted in a proprietary pipeline of orally-delivered and injectable protein replacement products. As a company, we are committed to improving the quality of life for patients.

Altus History

Altus was created in 1993 to research and refine our proprietary protein crystallization and cross-linking technology. Crystallization and cross-linking of proteins provide significant improvements in stability and concentration of proteins which leads to the opportunity for oral and parenteral delivery of proteins.

In 1999, Altus scientists found that the technology enabled the crystallization of all types of proteins into pure, stable protein crystals useful in a wide range of therapeutic applications. Strengthened by an established intellectual property base, Altus has emerged as the leader in protein crystallization within the rapidly growing biopharmaceutical industry.

Today, Altus is building a robust pipeline of products to treat a number of serious medical conditions associated with chronic gastrointestinal and metabolic disease areas. Our vision is to be the worldwide leader in the rapid and efficient development of valuable orally-delivered and injectable protein replacement products to meet unmet medical needs.

Altus in the News

New York Times 01 April 2008 article

Seeking Alternatives to Animal-Derived Drug

This website contains certain “forward-looking” statements. These statements are based on the current estimates and assumptions of Altus Pharmaceuticals Inc. (“Altus” or “the Company”) as of the date of this presentation and are subject to uncertainties and changes in circumstances. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Actual results may vary materially from the expectations contained herein. When used herein, the words “may”, “will”, “should”, “could”, “would”, “plan”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “potential” and “expect” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Altus to be materially different from those reflected in such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings “Special Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company's most recent annual or quarterly filing with the Securities and Exchange Commission , as well as those set forth in the Company's other filings with the Securities and Exchange Commission. Except to the extent required by applicable securities laws, Altus is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements or materials contained on a page of this website are made only as of the date of revision set forth on that page.